Most bone marrow transplant recipients are infertile due to reversible or irreversible testicular failure. However, little is known about the gonadotoxic potential of the newly introduced nonmyeloablative transplants. We undertook a 24-month longitudinal study in a cohort of 32 recipients of nonmyeloablative transplantation to test whether the combined regimen of fludarabine, melphalan and CAMPATH-1H can induce damage to germ cell (GC) and Leydig cell (LC) compartments. Testicular function was assessed immediately prior to transplantation and at four time points post-transplant to compare hormonal levels before and after the procedure. Two other groups treated with BEAM-and TBI-related regimes were also included in the study group for comparative purposes. GC function was assessed by measuring basal serum follicle stimulating hormone (FSH). LC function was assessed by measuring basal luteinising hormone (LH) and testosterone (T) levels. LC reserve was assessed by measuring the T/LH ratio. As a group, patients who received a non myeloablative transplant sustained severe damage to the GC compartment, as evident from a substantial elevation in the FSH level post-transplant (12 IU/l vs 18.4 IU/l, Po0.001). Similar to the GC injury, patients as a group sustained significant damage to the LC compartment following the transplant (5.4 IU/l vs 9.6 IU/ l, Po0.001). In general, patients had reduced LC reserve post-BMT, as evident from a diminished T/LH ratio (2.6 pretransplant vs 1.6 post-transplant P ¼ 0.05). Patients who received a nonmyeloablative transplant had a similar effect on the GC and LC compartments compared to those who had a BEAM autograft. On the other hand, patients who received a TBI-based transplant sustained more damage to their GC and LC compartments compared to those who received a nonmyeloblative transplant; however, this was not statistically significant (P ¼ 0.09). Our data suggest that this type of regimen is potentially gonadotoxic and consideration should be given to fertility counselling and testosterone replacement therapy posttransplant.
Summary:
Most bone marrow transplant recipients are infertile due to reversible or irreversible testicular failure. However, little is known about the gonadotoxic potential of the newly introduced nonmyeloablative transplants. We undertook a 24-month longitudinal study in a cohort of 32 recipients of nonmyeloablative transplantation to test whether the combined regimen of fludarabine, melphalan and CAMPATH-1H can induce damage to germ cell (GC) and Leydig cell (LC) compartments. Testicular function was assessed immediately prior to transplantation and at four time points post-transplant to compare hormonal levels before and after the procedure. Two other groups treated with BEAM-and TBI-related regimes were also included in the study group for comparative purposes. GC function was assessed by measuring basal serum follicle stimulating hormone (FSH). LC function was assessed by measuring basal luteinising hormone (LH) and testosterone (T) levels. LC reserve was assessed by measuring the T/LH ratio. As a group, patients who received a non myeloablative transplant sustained severe damage to the GC compartment, as evident from a substantial elevation in the FSH level post-transplant (12 IU/l vs 18.4 IU/l, Po0.001). Similar to the GC injury, patients as a group sustained significant damage to the LC compartment following the transplant (5.4 IU/l vs 9.6 IU/ l, Po0.001). In general, patients had reduced LC reserve post-BMT, as evident from a diminished T/LH ratio (2.6 pretransplant vs 1.6 post-transplant P ¼ 0.05). Patients who received a nonmyeloablative transplant had a similar effect on the GC and LC compartments compared to those who had a BEAM autograft. On the other hand, patients who received a TBI-based transplant sustained more damage to their GC and LC compartments compared to those who received a nonmyeloblative transplant; however, this was not statistically significant (P ¼ 0.09). Our data suggest that this type of regimen is potentially gonadotoxic and consideration should be given to fertility counselling and testosterone replacement therapy posttransplant. Improved transplant technology has markedly increased the use of bone marrow/stem cell transplantation for the treatment of haematological malignancies. Most transplant regimes consist of alkylating drugs combined with or without total body irradiation (TBI), either of which can induce hypergonadotrophic hypogonadism (primary testicular failure) with severe germ cell (GC) injury and even Leydig cell (LC) insufficiency (LCI). The impact of such damage has important implications on fertility and sexual function, especially in adolescents and young adults. The degree to which testicular function is affected is dose and agent dependent. 1, 2 Although gonadotoxicity can occur from pretransplant chemotherapy, 3 transplant regimens increase the risk of severe and more often irreversible gonadal damage. In a recent large survey conducted by the working party of the European Group for Blood and Marrow Transplantation (EBMT) for late effects, relating to 19 412 allogeneic and 17 950 autologous transplants, we showed that the overall pregnancy rate is only 0.6%, indicating that BMT patients rarely become parents. 4 In recent years, in an effort to reduce the short-and longterm toxicity associated with myeloablative transplants, conditioning regimens of reduced intensity have been developed. We have introduced such a protocol based on fludarabine, CAMPATH-1H and melphalan, and we have reported lower rates of nonrelapse mortality and a low incidence of graft-versus-host disease (GVHD). 5 Melphalan is a bifunctional alkylating agent, which is closely related to the highly mutagenic chemical chlorambucil, and forms DNA crosslinks. 6 It can induce mutagenesis in mice at the pre-and post-GC cell stage of spermatogenesis. 7 It can also induce dominant lethal mutation and heritable translocations in postmeiotic germ cells, particularly in early-mid spermatids. 8 Fludarabine is a purine analogue. However, little is known about it in relation to gonadotoxicity. We have recently reported that it can induce sperm-DNA damage in humans, which may persist for several months after the return of spermatogenesis. 9 The primary end point of this study was to investigate whether the combined regimen of fludarabine, melphalan and CAMPATH-1H can induce damage to GC and LC compartments. A second end point was to compare this protocol with regimens used in myeloablative transplants.
Patients and methods
A total of 32 males who had undergone a nonmyeloablative transplant for a haematological malignancy and survived for at least 6 months post-transplant were studied. The median age was 43.5 years (range 23-55). One patient had acute myeloid leukaemia (AML), One chronic lymphocytic leukaemia (CLL), two chronic myeloid leukaemia (CML), five Hodgkin's lymphoma (HL), six low-grade nonHodgkin's lymphoma (LGNHL), 13 multiple myeloma (MM) and four high-grade NHL (HGNHL). At transplant, 26 patients were in partial remission, four in complete remission (CR), One in chronic phase (CP) and one had refractory disease (RD). In all, patients had previously failed an autologous transplant.
Conditioning consisted of CAMPATH-1H 20 mg/day on days À8 to À4, fludarabine 30 mg/m 2 on days À7 to À3 and melphalan 140 mg/m 2 on day À2. In total, 17 recipients received unmanipulated G-CSF-mobilised peripheral blood stem cells on days 0 and +1 from their HLA identical siblings. One patient received a syngeneic stem cell transplant, while 14 patients received unmanipulated marrow from matched unrelated donors. GVHD prophylaxis was with cyclosporin A. All 32 patients engrafted and the median time to achieve neutrophils 40.5 Â 10 9 /l was 12 days (10-23) and platelets 420 Â 10 9 /l 13 days (9-96). One patient died from fungal pneumonia 6 months posttransplant, one from disease relapse and one from grade IV GVHD post-DLI. The incidence of acute GVHD was very low and 7/8 patients who developed acute GVHD were recipients of a MUD transplant. Two patients developed grade I and six patients grade II aGVHD, which was controlled with steroids and appropriate dose adjustment of cyclosporin A. Patient characteristics and endocrine data pre-and post-transplant are given in Table 1 .
In all, 60 patients from our institution who had received an autologous transplant with BEAM chemotherapy (carmustin 300 mg/m 2 on day À6, etoposide 200 mg/m 2 o.d. on days À5 to À2, cytarabine 200 mg/m 2 b.d. on days À5 to À2, and melphalan 140 mg/m 2 on day À1) and 21 recipients of a TBI-based allogeneic transplant were also studied for comparative reasons.
Endocrine assessment
GC function was assessed by measuring basal serum follicle stimulating hormone (FSH). LC function was assessed by measuring basal luteinising hormone (LH) and testosterone (T) levels. LC reserve was assessed by the T/LH ratio. 10 Biochemical GC and LC damage was characterised according to our previously published protocol.
3 Elevated FSH and LH levels of 410 IU/l were used as markers of GC and LC damage, respectively. Hypotestosteronaemia was defined as T values of o10 nmol/l. The T/LH ratio was considered to be abnormal if values were o2.5. The basal levels of all hormones were measured immediately prior to transplant. Post-transplant assessment was made wherever possible at four points: 3-6 months, 7-12 months, 12-18 months and 19-24 months post-transplant. The most recent follow-up was considered as the most appropriate measurement reflecting the gonadal status post-transplant and was used for the purpose of the analysis. All patients also had the thyroid function test (free thyroxine, TSH) and serum prolactin assays (data not shown).
Endocrine assays
Endocrine tests (FSH, LH, testosterone) were undertaken at 9-10 am to avoid the circadian and diurnal variation of hormones. Serum levels of FSH, LH and testosterone were measured by radioimmunoassay by a double antibody technique using commercially available kits. 3 The reference ranges of hormones in our laboratory were as follows: FSH and LH 2-10 IU/l; testosterone 10-25 nmol/l.
Statistics
The Wilcoxon signed-rank test was used to compare pre-vs post-transplant hormone levels. The Wilcoxon rank-sum (Mann-Whitney) test was used to compare differences in post-vs pretransplant hormone levels between patients who had received a non myeloablative transplant with those who had received either a TBI-based allogeneic transplant or an autologous marrow/stem cell transplant with BEAM chemotherapy.
Results

GC injury
As a group, patients who had received a nonmyeloablative transplant sustained severe damage to the GC compartment, as evident from a substantial elevation in the FSH level post-transplant (median FSH pretransplant 12 IU/l, median FSH post-transplant 18.4 IU/l, Po0.001) (Figure 1 ). Although pretransplant FSH data were unavailable in 6/32 patients, 9/26 patients had normal FSH levels pretransplant, and all except two (15,28) had high FSH levels post-transplant, indicative of GC injury induced by the transplant (Table 1 ). Of all, 11 patients had failed a previous autologous transplant. Longitudinal data were available only in seven regarding the GC compartment, and analysis showed that there was no significant difference in the FSH levels pre-vs post-transplant.
Leydig cell
Testosterone levels were available post-transplant in 28 patients. As a group the mean T level pre-vs post-BMT was normal. However, similar to the GC injury, as a group patients sustained significant damage to the LC compartment following the transplant (median LH pretransplant, 5.4 IU/l; median LH post-transplant, 9.6 IU/l, Po0.001) (Figure 2 ).
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It was interesting to note that despite having normal median LH levels pre-and post-transplant (potentially normal LC function), patients had LC dysfunction post-BMT induced by the conditioning. Reduced LC reserve was substantiated from diminished T/LH ratio (median ratio 2.6 pretransplant compared to 1.6 post-transplant) ( Table 1 ). When data of individual patients were analysed prior to BMT, only four had LCI with elevated LH levels: three patients (1,6,7) had compensated type (high LH and elevated T levels) and one patient (31) had frank LCI (elevated LH and low T levels). However, another three patients (8, 12, 29) had low T with normal LH levels. Post-transplant, only 4/28 had low T levels (8, 21,27,28). As a group 10/28 had reduced T/LH ratio pre-BMT and 20/28 had reduced T/LH ratio post-BMT. All 11 patients who had failed a previous autologous transplant sustained more damage following the nonmyeloablative transplant. (P ¼ 0.03). GC and LC compartments from patients who had undergone a nonmyeloablative transplant (as a first transplant) were compared with the relative compartment from a group of 21 patients who had a TBI-based allogeneic transplant, and with a group of 60 patients who had undergone a BEAM autologous stem cell/marrow transplant ( Table 2) .
Patients who received a TBI-based transplant showed a trend towards more damage to their GC compartment compared to those who received a nonmyeloablative transplant; however, this was not significant (P ¼ 0.09). No difference was observed in the LC compartment (P ¼ 0.3).
When recipients of a nonmyeloablative transplant were compared with those who had had a BEAM autograft, our analysis showed that both regimens had a similar effect on the GC (P ¼ 0.9) and LC (P ¼ 0.58) compartments.
Discussion
The results of this study show that our nonmyeloablative regimen is gonadotoxic and affects the GC as well as the LC compartments. Although many patients had GC injury prior to the transplant, even those with potentially intact germ cell function had a high risk of suffering GC damage due to transplantation. Patients as a group also suffered LC dysfunction, as evident from reduced T/LH ratios and significantly elevated LH levels post-transplantation. This is not surprising, as we have shown the same dose of melphalan (140 mg/m 2 ) to induce gonadal damage in male and female recipients of the BEAM autograft. 3 Although it may be expected that multiagent chemotherapy such as BEAM will induce more gonadal injury than melphalan and fludarabine alone, we have shown evidence of testicular injury even with fludarabine used as monotherapy in a patient with CLL. 9 Although there are no human data on reproductive or gonadotoxic potential in our nonmyeloablative protocol, melphalan protocols are less gonadotoxic than others using busulphan/cyclophosphamide or cyclophosphamide alone 11 based on an increased number of pregnancies. 12 However, these studies did not look into sperm parameters or gametogenic/steroidogenic endocrine function. Our study also showed that TBI-based regimens may cause more severe damage to the GC compartment compared to the nonmyeloablative regime. This is consistent with our previous work and that of others where TBI has been shown to be more gonadotoxic compared to other transplant regimens. It must be appreciated that CD52 (directed antigen for CAMPATH-1H) is a common surface antigen, which is expressed not only on haemopoietic cells but also on the spermatozoal membrane. Although its expression is restricted in the post-testicular event of spermiogenesis to the distal epididymis, 13 CAM-PATH-1H may indeed play a permissive role in the chemotherapeutic insult to the entire process of spermatogenesis and may contribute to spermatogenic arrest and infertility in recipients of a nonmyeloablative transplant. GC and LC injury can cause impaired spermatogenesis with infertility and andropause. 2 Several methods of preserving testicular function during potentially sterilising 2 Due to the potentially sterilising effect of this regimen, every effort should be made to cryopreserve sperm when possible before commencing the transplant. If this is not feasible due to irreversible gonadotoxicity pretransplant, or due to time constraints and inability to obtain semen samples from the affected subject (disease, pyrexia and psychological factors), future preservation of fertility may be possible by using donor sperm.
We therefore recommend informed counselling of patients undergoing nonmyeloablative therapy with fludarabine/melphalan regimens in view of the potential gonadotoxicity, which may have the following implications. Infertility due to GC damage may be induced and all patients treated with this regimen must be considered high risk for future paternity. If spermatogenesis is partially/ completely restored, paternity may have the potential to cause adverse fetal outcome, including miscarriage and congenital malformation in the offspring. The risk of genotoxicity is more real in pregnancies following artificial reproductive techniques (ART) with intracytoplasmic sperm injection (ICSI), where the natural protective barrier is lost. As melphalan is a proven mutagen at least in animals, as is fludarabine in humans, potential genotoxicity may have the future risk of congenital malformations or delayed milestones in affected individuals. Therefore, longterm follow-up of children is important, as recommended by Sanders et al, 14 in all recipients of BMT. The effect on LC function in transplant patients may cause sexual dysfunction, including diminished libido, and therefore long-term follow-up will be needed and consideration of testosterone replacement therapy for symptomatic LC insufficiency.
In conclusion, our data suggest that the combination used in this nonmyeloablative protocol (fludarabine, melphalan and CAMPATH-1H) does not spare the gonads. It can induce both GC injury as well as diminished LC reserve. These findings may have implications for fertility counselling in young adults and efforts should be focused on new regimens with less gonadotoxicity. Furthermore, testosterone replacement therapy should be considered in all patients presenting with symptoms of LC insufficiency or complete testicular failure.
